Assignee
BIOMARIN TECH BV
NL·14 granted patents·19 pending applications·176 citations·filing 2015–2024
Top patents by PatentIndex Score
33 records- 0199US10876114B2Methods and means for efficient skipping of at least one of the following exons of the human Duchenne muscular dystrophy gene: 43, 46, 50-53BIOMARIN TECH BV·Filed 2018·Granted Dec 29, 2020·36 cites·14 claims
- 0298US10533171B2Oligonucleotide comprising an inosine for treating DMDBIOMARIN TECH BV·Filed 2017·Granted Jan 14, 2020·36 cites·12 claims
- 0397USRE48468EMeans and methods for counteracting muscle disordersBIOMARIN TECH BV·Filed 2018·Granted Mar 16, 2021·25 cites·42 claims
- 0496US9890379B2Treatment of genetic disorders associated with DNA repeat instabilityBIOMARIN TECH BV·Filed 2015·Granted Feb 13, 2018·42 cites·17 claims
- 0595US10913946B2RNA modulating oligonucleotides with improved characteristics for the treatment of Duchenne and Becker muscular dystrophyBIOMARIN TECH BV·Filed 2018·Granted Feb 9, 2021·14 cites·3 claims
- 0694US2024360452A1Methods and means for efficient skipping of at least one of the following exons of the human duchenne muscular dystrophy gene: 43, 46, 50-53BIOMARIN TECH BV·Filed 2024·Application pending·0 cites
- 0793US11034956B2Oligonucleotide comprising an inosine for treating DMDBIOMARIN TECH BV·Filed 2019·Granted Jun 15, 2021·3 cites·10 claims
- 0892US10179912B2RNA modulating oligonucleotides with improved characteristics for the treatment of duchenne and becker muscular dystrophyBIOMARIN TECH BV·Filed 2016·Granted Jan 15, 2019·13 cites·9 claims
- 0991US10689646B2Treatment of genetic disorders associated with DNA repeat instabilityBIOMARIN TECH BV·Filed 2017·Granted Jun 23, 2020·4 cites·16 claims
- 1086US2024141339A1Oligonucleotide Comprising Inosine for Treating DMDBIOMARIN TECH BV·Filed 2023·Application pending·0 cites
- 1184US2023151362A1Methods and means for efficient dkipping of exon 45 in duchenne muscular dystrophy pre-mrnaBIOMARIN TECH BV·Filed 2022·Application pending·0 cites
- 1281US11427820B2Methods and means for efficient skipping of exon 45 in Duchenne muscular dystrophy pre-mRNABIOMARIN TECH BV·Filed 2019·Granted Aug 30, 2022·0 cites·10 claims
- 1379US11634714B2Oligonucleotide comprising an inosine for treating DMDBIOMARIN TECH BV·Filed 2021·Granted Apr 25, 2023·0 cites·9 claims
- 1478US2021139904A1Methods and means for efficient skipping of at least one of the following exons of the human duchenne muscular dystrophy gene: 43, 46, 50-53BIOMARIN TECH BV·Filed 2020·Application pending·0 cites
- 1576US12331293B2Bispecific antisense oligonucleotides for dystrophin exon skippingBIOMARIN TECH BV·Filed 2019·Granted Jun 17, 2025·1 cites·15 claims
- 1675US11274299B2Methods and means for treating DNA repeat instability associated genetic disordersBIOMARIN TECH BV·Filed 2019·Granted Mar 15, 2022·0 cites·25 claims
- 1774US10246707B2Method for efficient exon (44) skipping in duchenne muscular dystrophy and associated meansBIOMARIN TECH BV·Filed 2015·Granted Apr 2, 2019·1 cites·12 claims
- 1872US2019112604A1METHODS AND MEANS FOR EFFICIENT SKIPPING OF EXON 45 IN DUCHENNE MUSCULAR DYSTROPHY PRE-mRNABIOMARIN TECH BV·Filed 2018·Application pending·0 cites
- 1972US2019119679A1METHODS AND MEANS FOR EFFICIENT SKIPPING OF EXON 45 IN DUCHENNE MUSCULAR DYSTROPHY PRE-mRNABIOMARIN TECH BV·Filed 2018·Application pending·0 cites
- 2072US2019177725A1METHODS AND MEANS FOR EFFICIENT SKIPPING OF EXON 45 IN DUCHENNE MUSCULAR DYSTROPHY PRE-mRNABIOMARIN TECH BV·Filed 2019·Application pending·0 cites
- 2170US2021207138A1Method for efficient exon (44) skipping in duchenne muscular dystrophy and associated meansBIOMARIN TECH BV·Filed 2020·Application pending·0 cites
- 2270US2021108204A1RNA Modulating Oligonucleotides with Improved Characteristics for the Treatment of Duchenne and Becker Muscular DystrophyBIOMARIN TECH BV·Filed 2020·Application pending·0 cites
- 2368US2023330128A1Oligomers having bicyclic scaffold moietiesBIOMARIN TECH BV·Filed 2023·Application pending·0 cites
- 2467US2017044534A1Methods and means for efficient skipping of at least one of the following exons of the human duchenne muscular dystrophy gene: 43, 46, 50-53BIOMARIN TECH BV·Filed 2016·Application pending·0 cites
- 2566US2017107512A1METHODS AND MEANS FOR EFFICIENT SKIPPING OF EXON 45 IN DUCHENNE MUSCULAR DYSTROPHY PRE-mRNABIOMARIN TECH BV·Filed 2016·Application pending·0 cites
- 2664US2016304864A1Means and methods for counteracting muscle disordersBIOMARIN TECH BV·Filed 2016·Application pending·0 cites
- 2762US2019292541A1Method for efficient exon (44) skipping in duchenne muscular dystrophy and associated meansBIOMARIN TECH BV·Filed 2019·Application pending·0 cites
- 2861US2016264967A1Oligonucleotide comprising an inosine for treating dmdBIOMARIN TECH BV·Filed 2016·Application pending·0 cites
- 2960US11459358B2Substances for targeting various selected organs or tissuesBIOMARIN TECH BV·Filed 2017·Granted Oct 4, 2022·1 cites·17 claims
- 3059US2022098586A1OligonucleotideBIOMARIN TECH BV·Filed 2021·Application pending·0 cites
- 3154US2018066256A1RNA Modulating Oligonucleotides with Improved Characteristics for the Treatment of Neuromuscular DisordersBIOMARIN TECH BV·Filed 2017·Application pending·0 cites
- 3246US2018028554A1Oligomers Having Bicyclic Scaffold MoeitiesBIOMARIN TECH BV·Filed 2017·Application pending·0 cites
- 3334US2017029820A1Compounds for treating, delaying and/or preventing a human genetic disorder such as myotonic dystrophy type i (dmi)BIOMARIN TECH BV·Filed 2016·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when BIOMARIN TECH BV files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →